Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.
Saved in:
| Title: | Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. |
|---|---|
| Authors: | Fransson Å; Aprea AB, Solna, Sweden., Glaessgen D; Karolinska University Hospital, Stockholm, Sweden., Alfredsson J; Aprea AB, Solna, Sweden., Wiman KG; Karolinska Institutet Dept. of Oncology-Pathology, Cancer Center Karolinska (CCK), Stockholm, Sweden., Bajalica-Lagercrantz S; Karolinska University Hospital, Stockholm, Sweden.; Karolinska Institutet Dept. of Oncology-Pathology, Cancer Center Karolinska (CCK), Stockholm, Sweden., Mohell N; Aprea AB, Solna, Sweden. nina.mohell@aprea.com. |
| Source: | Journal of ovarian research [J Ovarian Res] 2016 May 14; Vol. 9 (1), pp. 27. Date of Electronic Publication: 2016 May 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101474849 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-2215 (Electronic) Linking ISSN: 17572215 NLM ISO Abbreviation: J Ovarian Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
